Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Postmarket Surveillance
Federal Register, Volume 81 Issue 174 (Thursday, September 8, 2016)
Federal Register Volume 81, Number 174 (Thursday, September 8, 2016)
Notices
Pages 62142-62143
From the Federal Register Online via the Government Publishing Office www.gpo.gov
FR Doc No: 2016-21554
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Docket No. FDA-2013-N-0557
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Postmarket Surveillance
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by October 11, 2016.
ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written
Page 62143
comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-0449. Also include the FDA docket number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 10A63, 11601 Landsdown St., North Bethesda, MD 20852, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Postmarket Surveillance--21 CFR Part 822--OMB Control Number 0910-
0449--Extension
Section 522 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360l) authorizes FDA to require a manufacturer to conduct postmarket surveillance (PS) of any device that meets the criteria set forth in the statute. The PS regulation establishes procedures that FDA uses to approve and disapprove PS plans. The regulation provides instructions to manufacturers so they know what information is required in a PS plan submission. FDA reviews PS plan submissions in accordance with part 822 (21 CFR part 822) in Sec. Sec. 822.15 through 822.19 of the regulation, which describe the grounds for approving or disapproving a PS plan. In addition, the PS regulation provides instructions to manufacturers to submit interim and final reports in accordance with Sec. 822.38. Respondents to this collection of information are those manufacturers who require postmarket surveillance of their products.
In the Federal Register of April 28, 2016 (81 FR 25409), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.
FDA estimates the burden of this collection of information as follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
Activity/21 CFR section Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
Postmarket surveillance 131 1 131 120 15,720
submission (Sec. Sec. 822.9
and 822.10)....................
Changes to PS plan after 15 1 15 40 600
approval (Sec. 822.21).......
Changes to PS plan for a device 80 1 80 8 640
that is no longer marketed
(Sec. 822.28)................
Waiver (Sec. 822.29).......... 1 1 1 40 40
Exemption request (Sec. 16 1 16 40 640
822.30)........................
Periodic reports (Sec. 822.38) 131 3 393 40 15,720
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 33,360
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Explanation of Reporting Burden Estimate: The burden captured in table 1 of this document is based on the data from FDA's internal tracking system. Sections 822.26, 822.27, and 822.34 do not constitute information collection subject to review under the PRA because it entails no burden other than that necessary to identify the respondent, the date, the respondents address, and the nature of the instrument (See 5 CFR 1320.3(h)(1)).
Table 2--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
Activity/21 CFR section Number of records per Total annual burden per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
Manufacturer records (Sec. 131 1 131 20 2,620
822.31)........................
Investigator records (Sec. 393 1 393 5 1,965
822.32)........................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 4,585
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Explanation of Recordkeeping Burden Estimate: FDA expects that at least some of the manufacturers will be able to satisfy the PS requirement using information or data they already have. For purposes of calculating burden, however, FDA has assumed that each PS order can only be satisfied by a 3-year clinically based surveillance plan, using three investigators. These estimates are based on FDA's knowledge and experience with postmarket surveillance.
Dated: September 1, 2016.
Leslie Kux,
Associate Commissioner for Policy.
FR Doc. 2016-21554 Filed 9-7-16; 8:45 am
BILLING CODE 4160-01-P
